Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Soar on Upgrade

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom climbed more than 20 percent in Tuesday afternoon trade after an investment analyst upgraded the firm's shares and significantly raised the bank's price target on the stock.

Cantor Fitzgerald analyst Pamela Bassett raised the bank's rating on Sequenom's stock to "buy" from "hold" and raised the bank's price target on the stock to $16 from $4. She cited the firm's diagnostic test pipeline, the upcoming launch of the next version of its MassArray platform, and the recent settlement of a lawsuit as key reasons for the upgrade.

In mid-January, the firm agreed to pay $14 million to settle a class action lawsuit brought by shareholders against the company related to the mishandling of data surrounding SEQureDx, a non-invasive test for fetal gene and chromosome abnormalities being developed by the company.

In Tuesday afternoon trade on the Nasdaq, shares of Sequenom were up 20 percent at $8.29.

As reported yesterday by GenomeWeb Daily News, Sequenom's shares were up 62 percent in February, boosted by the launch of a couple of molecular diagnostic tests.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.